These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23779109)

  • 21. The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site.
    Wong E; Maretzky T; Peleg Y; Blobel CP; Sagi I
    J Biol Chem; 2015 May; 290(19):12135-46. PubMed ID: 25795784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains.
    Gerhardt S; Hassall G; Hawtin P; McCall E; Flavell L; Minshull C; Hargreaves D; Ting A; Pauptit RA; Parker AE; Abbott WM
    J Mol Biol; 2007 Nov; 373(4):891-902. PubMed ID: 17897672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain.
    Lorenzen I; Trad A; Grötzinger J
    Biochem Biophys Res Commun; 2011 Nov; 415(2):330-6. PubMed ID: 22033402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human and Murine Interleukin 23 Receptors Are Novel Substrates for A Disintegrin and Metalloproteases ADAM10 and ADAM17.
    Franke M; Schröder J; Monhasery N; Ackfeld T; Hummel TM; Rabe B; Garbers C; Becker-Pauly C; Floss DM; Scheller J
    J Biol Chem; 2016 May; 291(20):10551-61. PubMed ID: 26961870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
    Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
    Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways.
    Dang M; Armbruster N; Miller MA; Cermeno E; Hartmann M; Bell GW; Root DE; Lauffenburger DA; Lodish HF; Herrlich A
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9776-81. PubMed ID: 23720309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression profile of ADAM10 and ADAM17 in allergic rhinitis.
    Chueh HW; Park SK; Hur DY; Bae WY
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1036-41. PubMed ID: 26250527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.
    Esselens CW; Malapeira J; Colomé N; Moss M; Canals F; Arribas J
    Biol Chem; 2008 Aug; 389(8):1075-84. PubMed ID: 18979631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetraspanin 8 Subfamily Members Regulate Substrate-Specificity of a Disintegrin and Metalloprotease 17.
    Müller M; Saunders C; Senftleben A; Heidbuechel JPW; Halwachs B; Bolik J; Hedemann N; Röder C; Bauerschlag D; Rose-John S; Schmidt-Arras D
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of key sequence determinants for the inhibitory function of the prodomain of TACE.
    Gonzales PE; Galli JD; Milla ME
    Biochemistry; 2008 Sep; 47(37):9911-9. PubMed ID: 18707126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular design and structural optimization of potent peptide hydroxamate inhibitors to selectively target human ADAM metallopeptidase domain 17.
    Wang Z; Wang L; Fan R; Zhou J; Zhong J
    Comput Biol Chem; 2016 Apr; 61():15-22. PubMed ID: 26709988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
    Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
    Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalytic properties of ADAM12 and its domain deletion mutants.
    Jacobsen J; Visse R; Sørensen HP; Enghild JJ; Brew K; Wewer UM; Nagase H
    Biochemistry; 2008 Jan; 47(2):537-47. PubMed ID: 18081311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans.
    Janes PW; Saha N; Barton WA; Kolev MV; Wimmer-Kleikamp SH; Nievergall E; Blobel CP; Himanen JP; Lackmann M; Nikolov DB
    Cell; 2005 Oct; 123(2):291-304. PubMed ID: 16239146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secreted Frizzled-related protein 3 (sFRP3)-mediated suppression of interleukin-6 receptor release by A disintegrin and metalloprotease 17 (ADAM17) is abrogated in the osteoarthritis-associated rare double variant of sFRP3.
    Oldefest M; Düsterhöft S; Desel C; Thysen S; Fink C; Rabe B; Lories R; Grötzinger J; Lorenzen I
    Biochem J; 2015 Jun; 468(3):507-18. PubMed ID: 25846075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
    Araya HF; Sepulveda H; Lizama CO; Vega OA; Jerez S; Briceño PF; Thaler R; Riester SM; Antonelli M; Salazar-Onfray F; Rodríguez JP; Moreno RD; Montecino M; Charbonneau M; Dubois CM; Stein GS; van Wijnen AJ; Galindo MA
    J Cell Biochem; 2018 Nov; 119(10):8204-8219. PubMed ID: 29923217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation.
    Goth CK; Halim A; Khetarpal SA; Rader DJ; Clausen H; Schjoldager KT
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14623-8. PubMed ID: 26554003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity.
    Gao W; Anderson PJ; Sadler JE
    Blood; 2008 Sep; 112(5):1713-9. PubMed ID: 18492952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
    Pruessmeyer J; Ludwig A
    Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
    Liu S; Liu S; Wang Y; Liao Z
    Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.